Microglial polarization refers to the functional specialization of microglia into distinct phenotypic states in response to environmental cues. This process is central to neuroinflammation in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Recent advances in single-cell RNA sequencing (scRNA-seq) have revolutionized our understanding of microglial heterogeneity, revealing that microglia exist in a continuum of states rather than discrete M1/M2 categories[1][2].
M1-polarized microglia represent the pro-inflammatory, classically activated state induced by IFN-γ, LPS, and damage-associated molecular patterns (DAMPs). Key characteristics include[3]:
Key transcription factors: NF-κB, STAT1, IRF5
Surface markers: CD86, MHC class II, iNOS, CD32
M2 microglia are associated with anti-inflammatory, repair-oriented functions:
Key characteristics:
Key transcription factors: STAT6, STAT3, PPARγ, IRF4
Surface markers: CD206 (mannose receptor), Arg1, Ym1, CD163
The M1/M2 framework, while useful conceptually, has significant limitations[4]:
DAM were first identified through scRNA-seq analysis of 5xFAD mouse models by Keren-Shaul et al. (2017)[5]. This landmark study revealed a unique microglial population that emerges specifically in response to neurodegeneration, characterized by:
DAM develop through a TREM2-dependent two-stage process[5:1][6]:
Stage 1 (TREM2-independent):
Stage 2 (TREM2-dependent):
Key studies establishing DAM across models:
| Study | Model | Key Findings |
|---|---|---|
| Keren-Shaul et al., 2017 | 5xFAD mice | First DAM characterization; TREM2-dependent |
| Mathys et al., 2019 | 5xFAD/APP mice | Temporal dynamics of DAM evolution |
| Zhou et al., 2020 | AD human brain | DAM signature in human AD tissue |
| Chen et al., 2020 | PD models | DAM in α-synuclein pathology |
| Deczkowska et al., 2017 | Various | DAM as universal response to neurodegeneration |
DAM signatures have been identified in human brain tissue from AD, PD, ALS, and MS patients[7][8], demonstrating conservation across species and disease contexts.
Aging-Related Microglia (ARM) represent a distinct state associated with brain aging, characterized by chronic, low-grade neuroinflammation termed "inflammaging"[9][10]. Unlike DAM, ARM develops in the absence of overt pathology and is driven by cumulative cellular stress.
Key scRNA-seq studies of aging microglia:
Hammond et al. (2019) - Aging Mouse Cortex[11]:
Mrdjen et al. (2019) - Aging Human Brain[12]:
O'Korontinos et al. (2022) - Human Aging[13]:
While ARM and DAM share some gene expression changes, they represent distinct states:
| Feature | ARM | DAM |
|---|---|---|
| Trigger | Aging | Neurodegeneration |
| TREM2-dependence | Partial | Required for Stage 2 |
| Spatial pattern | Distributed | Plaque/lesion-associated |
| reversibility | Partially reversible | Variable |
LDAM were identified as a distinct microglial subset characterized by intracellular lipid droplet accumulation, first characterized by Marschallinger et al. (2020)[14] and subsequently confirmed in aging and AD brains.
LDAM are defined by[14:1][15]:
LDAM accumulate with aging and in AD[15:1]:
LDAM represent a therapeutic target:
Key microglial scRNA-seq datasets:
In Alzheimer's disease, microglia adopt complex phenotypic states that evolve throughout disease progression. During early stages, microglia surrounding amyloid plaques exhibit DAM characteristics, with upregulation of TREM2, APOE, and complement genes. The TREM2 R47H variant, which impairs microglial phagocytic function, significantly increases AD risk, highlighting the critical role of microglial activation in amyloid clearance [1:1][2:1].
Microglial phenotypes in AD vary by plaque proximity:
The APOE4 allele profoundly affects microglial behavior in AD:
In Parkinson's disease, microglia adopt disease-associated states in response to α-synuclein pathology. Unlike AD, where amyloid plaques drive DAM formation, PD microglia respond to:
Key microglial markers in PD:
Levodopa and dopaminergic therapies modulate microglial responses, potentially explaining variable treatment responses.
Microglia in ALS exhibit complex, often contradictory phenotypes. Both protective and toxic microglial states exist:
Neuroprotective features:
Neurotoxic features:
The SOD1 G93A mouse model reveals time-dependent microglial shifts:
Microglial phenotypes in MS differ from other neurodegenerative diseases due to the autoimmune component. Key states include:
Active lesions:
Chronic lesions:
The transcriptional regulation of microglial polarization involves complex networks:
Pro-inflammatory (M1) transcription factors:
Anti-inflammatory (M2) transcription factors:
Microglial phenotype is epigenetically regulated:
Metabolism dictates microglial phenotype:
Pro-inflammatory metabolism:
Anti-inflammatory metabolism:
TREM2 represents a prime therapeutic target:
TREM2 agonists:
Mechanism:
Clinical considerations:
The NLRP3 inflammasome drives microglial inflammation:
Inhibitors in development:
Challenges:
CSF1R regulates microglial survival and proliferation:
Antagonists:
Effects:
Concerns:
Bulk RNA-seq has characterized microglial gene expression across conditions:
Key findings:
scRNA-seq revolutionized microglial biology:
Technical approaches:
Key discoveries:
Spatial methods preserve tissue architecture:
Technologies:
Applications:
Emerging approaches aim to replace dysfunctional microglia:
Methods:
Challenges:
Personalized approaches based on genetic background:
Considerations:
Keren-Shaul et al. A unique microglia type associated with restricting development of Alzheimer's Disease (2017). 2017. ↩︎ ↩︎
Zhou et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and independent microglial responses in Alzheimer's Disease (2020). 2020. ↩︎ ↩︎
Lupfer C, et al. APOE and microglial function in Alzheimer's disease (2024). 2024. ↩︎ ↩︎
Chen et al. A TREM2-independent pathway drives microglial activation in an alpha-synuclein model of Parkinson's Disease (2020). 2020. ↩︎ ↩︎
Trias E, et al. Astrocyte Notch signaling in ALS (2013). 2013. ↩︎ ↩︎ ↩︎
Baecher-Allan C, et al. Microglia in multiple sclerosis (2018). 2018. ↩︎ ↩︎
Zhou D, et al. Transcriptional networks in microglial polarization (2024). 2024. ↩︎ ↩︎
McGurn J, et al. Metabolic reprogramming in neurodegenerative microglia (2024). 2024. ↩︎ ↩︎
Cai Y, et al. TREM2 therapeutic targeting in neurodegenerative disease (2024). 2024. ↩︎ ↩︎
Elmore MR, et al. CSF1R as therapeutic target in neurodegeneration (2024). 2024. ↩︎ ↩︎
Masuda T, et al. Spatial and temporal heterogeneity of microglia (2019). 2019. ↩︎ ↩︎
Cherry et al. 'Neuroinflammation and M2 microglia: the good, the bad, and the inflamed (2014)'. 2014. ↩︎
'Ransohoff, A polarizing question: do M1 and M2 microglia exist? (2016)'. 2016. ↩︎
Deczkowska et al. 'Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration (2018)'. 2018. ↩︎ ↩︎
Hammond et al. Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan (2019). 2019. ↩︎ ↩︎